Systemic onset juvenile idiopathic arthritis (also known as Systemic juvenile idiopathic arthritis (sJIA)) is a disorder featuring inflammation, characterized by high spiking fevers, salmon-colored rash that comes and goes, and arthritis.
Symptoms are extreme fatigue accompanied by high fevers that rise daily to 102 F (39 C) or even higher and rapidly return to normal levels or below.
Fever spikes often occur at approximately the same time every day. A faint salmon colored skin rash characteristically comes and goes and does not itch.
Poor appetite, nausea, and weight loss are common. There is also commonly swelling of the lymph glands, enlargement of the spleen and liver, and sore throat.
Some patients develop inflammation around the heart (pericarditis) and lungs (pleuritis), with occasional fluid accumulation around heart (pericardial effusion) and lungs (pleural effusion).
Report Source: www.themarketreports.com/report/sy…e-review-h2-2017
- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders)
Report available at: www.themarketreports.com/report/buy-now/768417
Reasons To Access
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Got a question; ask us at: www.themarketreports.com/report/ask-your-query/768417
Category: Market Research Publishers and RetailersCompany about: The Market Reports aims to provide the best industry and market reports to a seeker. We are looking forward to a place where we are the one stop destination for all the report seekers irrespective of any country, category, domain, etc. We are always open on call and email (24*7) to your queries and very clean with the business methodology. Since we are dealing with so many Publishers, we can actually give you what suits best in accordance to your requirements.
For more information: